Cathepsin K inhibitor 2 是一种 cathepsin K 的有效抑制剂。其中 Cathepsin K (Cat K) 是一种半胱氨酸蛋白酶,在 CTSK 基因调控下表达,与骨质疏松症密切相关,能够水解胶原蛋白。Cathepsin K inhibitor 2 对骨关节炎表现出研究潜力。
Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V. It exhibits high affinity for these enzymes, with Ki values of 41 pM, 68 pM, and 53 pM, respectively. Moreover, Relacatib effectively inhibits endogenous cathepsin K in situ in human osteoclasts, as well as human osteoclast-mediated bone resorption, with IC 50 values of 45 nM and 70 nM, respectively. Additionally, in vitro studies demonstrate Relacatib's inhibitory effect on bone resorption in human tissue, while in vivo studies on cynomolgus monkeys further validate its efficacy in reducing bone resorption.
Gü1303 is a highly potent and reversible inhibitor of Cathepsin K (CatK), with a Ki value of 0.91 nM for mature CatK (mCatK). This compound effectively suppresses the autocatalytic activation of the CatK zymogen [1].
L-873724 inhibits bone resorption. L-873724 is an effective, selective, and reversible non-basic cathepsin K inhibitor (IC50s: 0.2, 178, 264, and 5239 nM for cathepsin K, cathepsin S, cathepsin L, cathepsin B, respectively). L-873724 also shows an IC50 of